Researchers Use CRISPR Technology to Treat Beta Thalassemia Patients
September 19, 2018| |
The first human trial in the U.S. using CRISPR gene-editing technology will soon be launched by Vertex Pharmaceuticals and CRISPR Therapeutics. The developers will conduct the trial to evaluate CTX001, a stem cell therapy developed using CRISPR to treat patients with beta thalassemia, a blood disorder characterized by low levels of hemoglobin which can lead to lack of oxygen in various parts of the body. The trial will be conducted at a German testing site.
Read more from Biocentury.
| |
Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
-
See more articles:
-
News from Around the World
- UN: Global Hunger Continues to Rise
- Kenyan Scientists Concerned Perceptions on GMOs May Slow Down GM Crops Commercialization
- Researchers to Improve Iron Toxicity Tolerance and Yield of Rice in Africa
- Burkina Faso Farmers Call for Return of Bt Cotton
- Scientists Crack A Code that Could Help Nourish the World
- How Plants Signal Danger Long Distances
- International Team Delivers Intermediate Wheatgrass Reference Genome
- Australian OGTR Invites Comments on GM Canola Field Trial
- John Innes Centre Leads Group's Call for Clarity after EU Ruling on Gene-Edited Crops
-
Research Highlights
- Vietnamese Scientists Develop Carotenoid-rich Maize
- Candidate Genes Related to Drought Stress Identified in Cotton
-
Beyond Crop Biotech
- Researchers Use CRISPR Technology to Treat Beta Thalassemia Patients
- Thousands of Breast Cancer Gene Versions Classified Using CRISPR-Cas9
- Scientists Engineer Powerful Weapon Against Antibiotic-Resistant Bacteria
-
From the BICs
- ISAAA Report on Biotech Crop Adoption Presented to Multiple Stakeholders in Japan
-
Plant
- CRISPR-Cas9 Reveals New Findings on miRNAs in Rice
- Bacterial Speck Resistance Developed in Tomato Using CRISPR-Cas9
- Rice Plant Architecture Engineered Using CRISPR-Cas9
- Scientists Develop Modified CRISPR-Cas9 System for Tetraploid Potato
-
Read the latest: - Biotech Updates (December 4, 2024)
- Gene Editing Supplement (November 27, 2024)
- Gene Drive Supplement (February 22, 2023)
-
Subscribe to BU: - Share
- Tweet